Surging Earnings Estimates Signal Upside for Doximity (DOCS) Stock
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Doximity Q2 Earnings: Positioning Is Paying Off
I rate Doximity a buy with a price target of $65, reflecting a 24% upside due to strong Q2 earnings and favorable industry trends. Doximity's Q2 earnings showed impressive revenue growth, margin expansion, and a revised forecast of 36% CAGR in revenue and 74% CAGR in Adjusted EBITDA. Positioned at the intersection of healthcare trends, Doximity offers cost-saving solutions that align with industry needs, supporting double-digit growth through 2030.
Dr. Martens upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Louise Singlehurst upgraded Dr. Martens to Neutral from Sell with a price target of 64 GBp, down from 71 GBp. The firm sees emerging valuation support post the recent de-rating of the shares. It expects Dr. Martens' EBIT margins to inflect positively into fiscal 2026 post three years of margin compression.
Why Doximity Stock Is Skyrocketing Today
The market loved what it saw from Doximity's second-quarter earnings.
Why Doximity Stock is Set to Open at Highest Point in Over 2 Years Friday
Doximity (DOCS) shares jumped nearly 40% in premarket trading Friday after the medical tech company's earnings and outlook came in above what analysts expected.
Doximity Stock Soars 42% Toward Best Day Ever. It's Not the Only Record.
The online medical platform reported quarterly revenue of $136.8 million and earnings of 30 cents a share, beating analysts expectations.
Doximity, Inc. (DOCS) Q2 2025 Earnings Call Transcript
Doximity, Inc. (NYSE:DOCS ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Perry Gold - Vice President of Investor Relations Jeff Tangney - Co-Founder and CEO Anna Bryson - Chief Financial Officer Nate Gross - Co-Founder and Chief Strategy Officer Conference Call Participants Glen Santangelo - Jefferies Johnathan McCary - Raymond James Stephanie Davis - Barclays Jared Haase - William Blair Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Dan Clark - Leerink Scott Schoenhaus - KeyBanc Scott Berg - Needham & Company Jailendra Singh - Truist Eric Percher - Nephron John Park - Morgan Stanley Operator Well, good day, everyone, and welcome to the Doximity Fiscal 2Q '25 Earnings Call. At this time, I would like to hand the call over to Mr.
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
Doximity (DOCS) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.22 per share a year ago.
Doximity (DOCS) Outperforms Broader Market: What You Need to Know
Doximity (DOCS) closed at $41.88 in the latest trading session, marking a +1.11% move from the prior day.
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Doximity (DOCS) closed at $41.42, indicating a -1.76% shift from the previous trading day.
3 Medical Services Stocks to Buy to Navigate Industry Challenges
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most.
Overlooked Stock: DOCS
Doximity (DOCS) is trading near its 52-week high after getting an upgrade from Barclays. George Tsilis talks about why the "LinkedIn for physicians" can be gaining investor interest.
